Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980127 | 0.83 | ITGB1 (0.53) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL3837352 | 0.79 | ITGB1 (0.45) | FFAR1ITGB1ITGA4DRD1CYP3A4 | |
| SCHEMBL5147705 | 0.75 | FFAR1 (0.34) | FFAR1DRD1 | |
| SCHEMBL5147590 | 0.75 | FFAR1 (0.45) | FFAR1DRD1GRM4MAPK8PTGER4 | |
| SCHEMBL3837359 | 0.75 | FFAR1 (0.35) | FFAR1ITGB1ITGA4DRD1GRM4 | |
| SCHEMBL5147512 | 0.75 | FFAR1 (0.38) | FFAR1ITGB1ITGA4DRD1GRM4 | |
| SCHEMBL2981066 | 0.72 | ITGB1 (0.51) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL5148581 | 0.71 | FFAR1 (0.36) | FFAR1ITGB1ITGA4DRD1GRM4 | |
| SCHEMBL2973984 | 0.71 | ITGB1 (0.55) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL5149383 | 0.70 | FFAR1 (0.37) | FFAR1DRD1GRM4PTGER4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
| EP-1780201-A2 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R&D Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | CELLTECH R&D LIMITED | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, AGTR2 | FFAR1 140/4885ITGB1 77/4885ITGA4 462/4885 |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | FFAR1 151/4885ITGB1 3/4885ITGA4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.